Umbralisib clinical trials
Also written TGR-1202 and RP5264.
How each study uses umbralisib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 5 Feb 2021 · UKONIQ · NDA 213176 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 16
TG Therapeutics, Inc. (13) · City of Hope Medical Center (2) · Columbia University (2) · National Cancer Institute (NCI) (1) · Jennifer R. Brown, MD, PhD (1) · University of Chicago (1) · Vanderbilt-Ingram Cancer Center (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Ublituximab (12) · Lenalidomide (2) · Acalabrutinib (1) · Tazemetostat (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses umbralisib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 29
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingPhase 2City of Hope Medical CenterNCT04783415Written as UmbralisibHow we know
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03269669Written as UmbralisibHow we know
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedPhase 1Vanderbilt-Ingram Cancer CenterNCT02493530Written as TGR-1202How we know
- Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaTerminatedPhase 2Massachusetts General HospitalNCT03919175Written as UmbralisibHow we know
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingPhase 2Jennifer R. Brown, MD, PhDNCT04624633Written as UmbralisibHow we know
- TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT04163718Written as UmbralisibHow we know
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingPhase 1University of ChicagoNCT03283137Written as TGR-1202How we know
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedPhase 3TG Therapeutics, Inc.NCT02612311Written as TGR-1202How we know
- A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLCompletedPhase 1Dana-Farber Cancer InstituteNCT02268851Written as TGR-1202How we know
- Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyTerminatedPhase 2TG Therapeutics, Inc.NCT02742090Written as UmbralisibHow we know
- Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)TerminatedPhase 2/3TG Therapeutics, Inc.NCT03801525Written as UmbralisibHow we know
- TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedPhase 2University of NebraskaNCT02874404Written as PI3K-delta Inhibitor TGR-1202How we know
- Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)TerminatedPhase 1/2University of Alabama at BirminghamNCT04692155Written as UmbralisibHow we know
- Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedPhase 2TG Therapeutics, Inc.NCT03828448Written as UmbralisibHow we know
- Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaCompletedPhase 2TG Therapeutics, Inc.NCT03364231Written as UmbralisibHow we know
- A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedPhase 2TG Therapeutics, Inc.NCT02656303Written as UmbralisibHow we know
- Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyTerminatedPhase 2Weill Medical College of Cornell UniversityNCT04149821Written as UmbralisibHow we know
- Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaWithdrawnPhase 1/2City of Hope Medical CenterNCT05152459Written as UmbralisibHow we know
- Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedPhase 2University of WashingtonNCT03776864Written as UmbralisibHow we know
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnPhase 1Yazeed SawalhaNCT04635683Written as UmbralisibHow we know
See all 29 studies that test umbralisib →
Given beside what is tested · 5 — umbralisib is usual care or a partner of the new treatment
- Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTerminatedPhase 1TG Therapeutics, Inc.NCT03671590Written as UmbralisibHow we know
- Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone LymphomaCompletedPhase 2University of Colorado, DenverNCT04508647Written as UmbralisibHow we know
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedPhase 2TG Therapeutics, Inc.NCT04016805Written as UmbralisibHow we know
- Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedPhase 1TG Therapeutics, Inc.NCT02535286Written as UmbralisibHow we know
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedPhase 1/2TG Therapeutics, Inc.NCT03379051Written as UmbralisibHow we know
Codes
What other systems call umbralisib · ClinicalTrials.gg INT000901
- MeSH (NLM) C000626319umbralisibOne source NLM
- UNII (FDA) 38073MQB2AUMBRALISIBConfirmed FDA, NLM, Wikidata
- RxNorm 2478439One source FDA
- Wikidata Q27088612umbralisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104413UmbralisibOne source FDA
- DrugBank DB14989One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626319 | umbralisib | One source NLM |
| UNII (FDA) | 38073MQB2A | UMBRALISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2478439 | — | One source FDA |
| Wikidata | Q27088612 | umbralisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104413 | Umbralisib | One source FDA |
| DrugBank | DB14989 | — | One source Wikidata |
Also registered as umbralisib tosylate (UNII FU8XW5V3FS · RxNorm 2478438).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.